The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

FDA approves Ipsen's Iqirvo for primary biliary cholangitis, ending a 10-year hiatus in new therapies for the rare cholestatic liver disease.

“If your itching is caused by a liver problem, there won’t be a skin rash or an insect bite,” the Liver Foundation says. The ...

(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.

According to the latest study from BCC Research, the "Liver Disease Treatments: The Global Market" is projected to increase from $46.0 ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

Elmore Leonard once said “I don’t have any of the modern electronics at all. I know the Internet would be a distraction. I ...

Primary Care. June 18, 2025 . 47 min listen. Artificial intelligence in medicine: Improving health care for physicians, with Anthony Chang, MD (Part 2) Hematology/Oncology. June 17, 2025 .

US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows ...